简介
Borja Ibáñez (Madrid, 1975) is Professor of Cardiovascular Research and Scientific Director at the Spanish National Center for Cardiovascular Research (CNIC) in Madrid, Spain, where he is also the Scientific Director of the center. He combines this role with clinical practice as an interventional cardiologist at University Hospital Fundación Jiménez Díaz. He is a group leader at the Spanish Network Center for Biomedical Research in Cardiovascular Diseases (CIBERCV).
After completing his cardiology training in Madrid, he moved to Mount Sinai Heart (New York, NY), where he obtained his PhD in the field of atherosclerotic plaque regression using recombinant HDL (apoA-I Milano). On returning to Spain, he established and leads the “Translational Laboratory for Cardiovascular Imaging and Therapy” at CNIC, closely integrated with the Cardiology Department at Fundación Jiménez Díaz. His research sits at the interface between basic and clinical science, focusing on acquired myocardial diseases (particularly myocardial infarction and cancer therapy–related cardiotoxicity) and atherosclerotic cardiovascular disease (ASCVD). While he has made major contributions to the understanding and treatment of acute coronary syndromes and myocardial infarction, in recent years his work has increasingly targeted the subclinical stages of ASCVD, with an emphasis on early detection of silent atherosclerosis through non-invasive imaging.
Prof. Ibáñez co-leads the REACT (Early Cure of Atherosclerosis) initiative and the PESA (Progression of Early Subclinical Atherosclerosis) study, both of which aim to develop precision medicine strategies to curb ASCVD by targeting atherosclerosis at its earliest stages. He has led multiple translational programs that have brought novel therapies and diagnostic tools from bench to bedside, and he has served as Principal Investigator of numerous multinational randomized clinical trials, including (among others) REBOOT, RESILIENCE, STREAMLINE, REACT, and METOCARD-CNIC, enrolling several thousands of patients.
He has co-authored more than 400 scientific publications, including seminal work in leading journals such as The New England Journal of Medicine, The Lancet, Science, Nature, Nature Medicine, Cell, European Heart Journal, Circulation, JACC, Circulation Research and Nature Communications (among others). His research has received over 105,000 citations, and he is listed as a Highly Cited Researcher by Web of Science. He coordinates several European Commission–funded projects spanning basic (ERC-CoG), clinical (H2020), and technological (IHI) research, and is co-inventor on multiple patents, notably the ultrafast CMR sequence ESSOS, which enables a comprehensive cardiac MRI study in under one minute.
Prof. Ibáñez has directed several congresses and conferences. He has directed 33 doctoral theses and supervised 8 postdoctoral fellows (some of them now serving as group leaders in different international centers).
Prof. Ibáñez has been recognized with numerous scientific awards, including the Banco Sabadell Award, Constantes y Vitales Award, Princesa de Girona Award, and Fundación Jesús Serra Award, among others. He is deeply involved in the development of clinical practice guidelines within the European Society of Cardiology (ESC), having served (among others) as Chairperson of the 2023 ESC Guidelines for the management of acute coronary syndromes and the 2017 ESC STEMI Guidelines.
